Latest revenue
$146.0K
as of 2025-09-30
Latest net income
$-2.6M
as of 2025-09-30
Net margin
-1778.1%
as of 2025-09-30
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $2.7M
- Enterprise value
- $2.7M
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $5.60
- 52-wk low
- $0.72
- Beta
- —
- Shares out
- 3.2M
5-year trend
What this company does
Item 1 – Business As used in this Report, unless the context otherwise requires, references to “we,” “us,” “our,” “Company,” “Tivic,” and “Tivic Health” refer to Tivic Health Systems, Inc, collectively with its subsidiary, on a consolidated basis. Business Overview Tivic™ Health Systems, Inc. is a late-stage biopharmaceutical company whose lead program is Entolimod™. Entolimod is a recombinant TLR5 agonist with an extensive preclinical and clinical data package supporting development as a medical countermeasure (MCM) for Acute Radiation Syndrome (ARS) and it subsyndromes, as well as for adjunct therapy for oncology indications, such as neutropenia. During fiscal year 2025, Tivic executed a…
AI summary unavailable — showing raw filing excerpt
Generated from VBIO's filing dated 2026-03-30
Key risks
Item 1A – Risk Factors You should carefully consider the risks described below, as well as the other information in this Report, including our financial statements and the related notes and the section entitled “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” before investing in our securities. The occurrence of any of the events or developments described below could harm our business, financial condition, operating results, and/or growth prospects. The risks described below are not the only ones facing us. Our business is also subject to the risks that affect many other companies, such as competition, labor relations, general economic conditions,…
AI summary unavailable — showing raw filing excerpt
Generated from VBIO's filing dated 2026-03-30
Profitability
Gross margin
0.3%
98.9%Operating margin
-725.8%
3.5%Net margin
-725.0%
3.4%Return on equity
-52.9%
76.3%Return on assets
-28.1%
86.1%Leverage
Debt / equity
0.88×
721.7%Debt / assets
46.9%
383.6%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | — | — | $-6.2M | -312.9% | — |
Q4 2025 2025-12-31 | — | — | $-2.8M | -92.9% | — |
Q3 2025 2025-09-30 | $146.0K | +15.9% | $-2.6M | -81.4% | -1778.1% |
Q2 2025 2025-06-30 | $86.0K | -38.6% | $-1.9M | -52.5% | -2245.3% |
Q1 2025 2025-03-31 | $70.0K | -79.0% | $-1.5M | -1.4% | -2145.7% |
Q4 2024 2024-12-31 | $180.0K | — | $-1.5M | — | -820.6% |
Q3 2024 2024-09-30 | $126.0K | -55.3% | $-1.4M | +18.7% | -1135.7% |
Q2 2024 2024-06-30 | $140.0K | -13.0% | $-1.3M | +40.4% | -904.3% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Electromedical & Electrotherapeutic Apparatus · SIC 3845
Your notes
Keep private notes on VBIO — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
No insider transactions on file for VBIO in the last 12 months.
Source: SEC Form 4 filings. Backfill runs nightly.
Who owns VBIO
No institutional holdings on file for VBIO yet.
Source: SEC Form 13F-HR. Updated quarterly (45-day filing lag).
Top questions investors are asking
Coming once VBIO's latest filing finishes processing.